Commercial Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch BioPharma DiveA strong performance from Mounjaro overseas boosted Lilly s results, and the company raised its guidance for the year for both profit and revenue.Read full story pharminent April 30, 2026 (Last updated: May 1, 2026) BioPharma Dive A strong performance from Mounjaro overseas boosted Lilly s results, and the company raised its guidance for the year for both profit and revenue. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly clocks 56% revenue increase in Q1 but declining prices stunt growthNext: UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy Related Stories Commercial Post-marketing oncology studies: Enabling faster recruitment and lower costs pharminent June 22, 2026 Commercial The first 14 days: How specialty programs set patients up for success pharminent June 22, 2026 Commercial Denali sells FDA voucher for $195M to support neurodegenerative pipeline pharminent June 19, 2026
